Showing 4641-4650 of 8791 results for "".
- To Keep Pace with Growth, Crown Builds Out Manufacturing Complexhttps://practicaldermatology.com/news/to-keep-pace-with-growth-crown-builds-out-manufacturing-complex/2461266/Crown Laboratories is adding 60,000 square feet to its manufacturing complex in Johnson City, TN. The facility is home to PanOxyl acne wash, Blue Lizard Australian Sunscreen, and Sarna anti-itch lotion. The additional 60,000 sq. ft. will bring the Lafe Cox Drive facility
- Systemic Inhibition of S100A9 May Reduce Severity of PsO, PsAhttps://practicaldermatology.com/news/systemic-inhibition-of-s100a9-may-reduce-severity-of-pso-psa/2461262/The severity of psoriasis and psoriatic arthritis can be reduced by inhibiting S100A9 systemically throughout the whole body rather than locally on the skin, according to a new study. By way of background, S100A9 activation in skin and immune cells has been identified as a risk factor f
- Vitamin D During Pregnancy May Cut Eczema Risk in Babieshttps://practicaldermatology.com/news/vitamin-d-during-pregnancy-may-cut-eczema-risk-in-babies/2461256/Taking Vitamin D supplements during pregnancy could substantially reduce the chances of babies developing atopic eczema, according to a new study by University of Southampton researchers. The research, published in the
- Phase 3 PSOARING 3 Long-Term Extension Study Data Positive for Tapinarof Creamhttps://practicaldermatology.com/news/phase-3-psoaring-3-long-term-extension-study-data-positive-for-tapinarof-cream/2461251/New data from the one-year safety and efficacy final analyses of the Phase 3 PSOARING 3 long-term, open-label extension (“LTE”) study of Dermavant Sciences' VTAMA (tapinarof) cream, 1% for the treatment of plaque psoriasis in adults was published in the
- FDA Clears Soligenix's Synthetic Hypericin for Phase 2 Clinical Trial in Psoriasishttps://practicaldermatology.com/news/fda-clears-soligenixs-synthetic-hypericin-for-phase-2-clinical-trial-in-psoriasis/2461250/The U.S. Food and Drug Administration (FDA) has cleared Soligenix’s Investigational New Drug (IND) application for a Phase 2a clinical trial of topically-applied SGX302 (synthetic hypericin). Patient enrollment is slated to begin in the fourth quarter of 2022. "Duri
- NYC PrideFest: Galderma Aesthetics to Participatehttps://practicaldermatology.com/news/nyc-pridefest-galderma-aesthetics-to-participate/2461249/Galderma is participating in New York City's official LGBTQIA+ Pride (NYC Pride) event. This month marks the official launch of Restylane's "XpresYourself" communications campaign, which gives a nod to Restylane's XpresHAn Technology™, a u
- Dermatologists Rule for Cosmetic Procedures and Skin Care Decisionshttps://practicaldermatology.com/news/dermatologists-rule-for-cosmetic-procedures-and-skin-care-decisions/2461241/Dermatologists rank as the number one influencer among 16 factors that impact consumers’ decisions to have a cosmetic procedure, according to the 2021
- Business News: Solta IPO Put on Icehttps://practicaldermatology.com/news/business-news-solta-ipo-put-on-ice/2461239/Bausch Health Companies Inc. is suspending its plans for the Solta IPO due to challenging market conditions and other factors. Bausch Health stated that the interests of the Company's stakeholders are best served in the near-term by focusing on driving Solta's revenue, profits a
- ProofPilot Wants You to Submit Research Ideas on Issues Concerning BIPOC Communitieshttps://practicaldermatology.com/news/proofpilot-wants-you-to-submit-research-ideas-on-issues-concerning-bipoc-communities/2461237/ProofPilot, a Software as a Service (SaaS) clinical trial research platform, is rolling out its first ever Open Invitation for Research, in partnership with the nonprofit organization
- Happify Health, Almirall Go Live with Digital Solution to Support Psoriasis Patientshttps://practicaldermatology.com/news/happify-health-almirall-go-live-with-digital-solution-to-support-psoriasis-patients/2461234/Happify Health and Almirall S.A.’s new digital platform Claro is live and now available to people with psoriasis in Spain, Italy and the United Kingdom. Claro was built to improve the mental well-being of people with psoriasis through cognitive behavioral therapy, positive psychology, and m